This site is intended for healthcare professionals

The latest treatments in NASH

Read time: 15 mins
Last updated:2nd Sep 2020
Published:21st Aug 2020
As lifestyle changes and surgery are not always a viable option for treating NASH, new treatments are sorely needed. Looking to the near future, find out which drug therapies for NASH are currently in Phase III trials.

Recently, diabetes therapeutics called glitazones (pioglitazone in particular) have been the focus of several studies for NASH treatment and studies show that the use of glitazones can lead to improvements in steatosis, fibrosis and hepatocellular ballooning (damage to liver cells), but at the cost of significant weight gain1.

Current guidelines suggest that pioglitazone can be used for the treatment of steatohepatitis in patients with biopsy-proven NASH2.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.